Fig. 2.

PLL dendrimer inhibits bFGF-induced angiogenesis in Matrigel plug assay after systemic (i.v.) administration in vivo biodistribution of PLL dendrimer after i.v. administration of 25 mg/kg as a single dose in tumor-bearing C57Bl/6 mice. (A) Percent injected dose per gram tissue at different time points and (B) percent injected dose per gram tissue in B16F10 tumors. Data expressed as the mean ± SD (n = 4) using tumor-bearing mice. (C) H&E-stained Matrigel plugs with arrows pointing at the microvessels and are significantly lower in PLL-dendrimer treated plugs. (D) Hemoglobin content in Matrigel plugs mixed with heparin and bFGF and implanted subcutaneously for 7 days in the abdominal region of C57/BL6 mice. Animals were injected via tail vein with 50 mg/kg/day PLL dendrimer (once daily, on days 1 and 2 postimplantation) or with PBS alone. Data expressed as a mean ± SD (n = 4) (^∗P < 0.05).